BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

day all lines have been placed on me to prevent any background noise after the company's remarks there will be a question and answer session if you would like to ask a question please press star followed by the number one on your telephone keypad if you would like to withdraw your question please press star one again thank you before we begin i would like to remind everyone that today's call may contain forward-looking statements within the meaning of the federal securities laws including but not limited to statements about Bridge Bio's future operating and financial performance, business plans, and prospects and strategy. These statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied in these forward-looking statements. For a discussion of these risks and uncertainties, Please refer to the disclosure in today's earnings release and BridgeBio's periodic reports and SEC filings. All statements made here are based on information available to BridgeBio as of today, and the company undertakes no obligation to update any forward-looking statements made during this call, except as required by law. With that completed, BridgeBio, you may begin your conference. Good afternoon and thank you for joining BridgeBio's Q1 2025 Earnings Conference Call. This is Chinmay Shukla, VP of Strategic Finance at BridgeBio. Today we will discuss our financial results for the first quarter of 2025 and provide an overview of how we measure success in our business. We'll provide insight into the early results from the launch of a Truebee, as well as provide an update on our pipeline, which has three phase three readouts expected in the next year, including our e...